Curable composition having an electron deficient olefin

Abstract

The invention relates to a curable composition having an electron deficient olefin.

Claims

1. A curable composition comprising: (a) at least one electron deficient olefin; (b) in addition to the at least one electron deficient olefin of (a), at least one compound having at least one electron deficient olefin functional group and at least one additional functional group selected from (i) (meth)acrylic esters, (ii) acrylonitriles, (iii) acrylamides, or (iv) styryl functional groups; (c) optionally, a cure system; and (d) at least one compound other than compounds of (b) having at least one curable functional group other than an electron deficient olefin, wherein the compound of (b) is a member selected from the group consisting of ##STR00035## wherein n is 2, 3 or 4 and Q is H or CH.sub.3, and wherein the compounds of (d) are selected from ##STR00036## wherein Rb is H or alkyl, R.sub.4 is alkyl, and v is 2-4.

2. The composition of claim 1, wherein the electron deficient olefin is a 2-cyanoacrylate within structure I: ##STR00037## wherein R.sup.1 is a member selected from the group consisting of C.sub.1-16 alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, aryl, allyl and haloalkyl groups.

3. The composition of claim 2, wherein the 2-cyanoacrylate is a member selected from the group consisting of methyl cyanoacrylate, ethyl cyanoacrylate, propyl cyanoacrylates, butyl cyanoacrylates, octyl cyanoacrylates, allyl cyanoacrylate, propargyl cyanoacrylate, -methoxyethyl cyanoacrylate and combinations thereof.

4. The composition of claim 1, wherein the electron deficient olefin is a methylidene malonate within structure II: ##STR00038## wherein R.sup.2 and R.sup.3 are each independently selected from alkyl, alkoxyalkyl, cycloalkyl, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, oxirane, episulfide, and oxetane groups.

5. The composition of claim 1, further comprising: (a) a stabilizer package comprising at least one free radical stabilizer and at least one anionic stabilizer; and (b) optionally, one or more additives selected from the group consisting of cure accelerators, thickeners, thixotropes, tougheners, thermal resistance-conferring agents, adhesion promoters and plasticizers.

6. The composition of claim 1, wherein the cure system is present and assists cure by a free radical mechanism, an ionic initiation, or a condensation reaction.

7. The composition of claim 5, wherein the cure system is triggered by exposure to photoirradiation, elevated temperature conditions, moisture, metal, air or anaerobic conditions and combinations thereof.

8. A curable composition comprising: (a) at least one electron deficient olefin; (b) in addition to the at least one electron deficient olefin of (a), at least one compound selected from the group consisting of ##STR00039## wherein n is 2, 3 or 4 and Q is H or CH.sub.3; (c) optionally, a cure system; and (d) at least one compound other than compounds of (b) having at least one curable functional group other than an electron deficient olefin, wherein the compound of (d) is selected from ##STR00040## wherein R.sub.1, R.sub.2, and R.sub.3 are the same or different and are selected from C.sub.1-4 alkyl or alkoxy, Rb is H or alkyl, and v is 1-3.

9. The composition of claim 1, further comprising a compound having a curable functional group selected from (meth)acrylates, acrylonitriles, acrylamides, vinyls, allyls, styrenes, maleimides, itaconimides, and nadimides.

10. The composition of claim 9, wherein the (meth)acrylate compound is selected from 2(2-ethoxyethoxy) ethyl (meth)acrylate, 2-phenoxyethyl (meth)acrylate, 3,3,5 trimethylcyclohexyl (meth)acrylate, alkoxylated lauryl (meth)acrylate, alkoxylated phenol (meth)acrylate, alkoxylated tetrahydrofurfuryl (meth)acrylate, caprolactone (meth)acrylate, cyclic trimethylolpropane formal (meth)acrylate, dicyclopentadienyl (meth)acrylate, diethylene glycol methyl ether (meth)acrylate, ethoxylated hydroxyethyl (meth)acrylates, ethoxylated nonyl phenol (meth)acrylates, isobornyl (meth)acrylate, isodecyl (meth)acrylate, isooctyl (meth)acrylate, lauryl (meth)acrylate, methoxy polyethylene glycol mono(meth)acrylates, octyldecyl (meth)acrylate, propoxylated allyl (meth)acrylates, stearyl (meth)acrylate, tetrahydrofurfuryl (meth)acrylates, tridecyl (meth)acrylate, triethylene glycol ethyl ether (meth)acrylates, 1,12-dodecanediol di(meth)acrylate, 1,3-butylene glycol di(meth)acrylate, 1,4-butanediol di(meth)acrylate, 1,6-hexanediol di(meth)acrylate, alkoxylated aliphatic di(meth)acrylate, alkoxylated cyclohexane dimethanol di(meth)acrylate, alkoxylated hexanediol di(meth)acrylate, alkoxylated neopentyl glycol di(meth)acrylate, cyclohexane dimethanol di(meth)acrylate, diethylene glycol di(meth)acrylate, dipropylene glycol di(meth)acrylate, ethoxylated bisphenol a di(meth)acrylates, ethylene glycol di(meth)acrylate, neopentyl glycol di(meth)acrylate, polyethylene glycol di(meth)acrylates, polypropylene glycol di(meth)acrylates, tetraethylene glycol di(meth)acrylate, tricyclodecane dimethanol di(meth)acrylate, triethylene glycol di(meth)acrylate, tripropylene glycol di(meth)acrylate, di-trimethylolpropane tetra(meth)acrylate, dipentaerythritol penta(meth)acrylate, ethoxylated pentaerythritol tetra(meth)acrylates, pentaerythritol tetra(meth)acrylate, ethoxylated trimethylolpropane tri(meth)acrylates, pentaerythritol tri(meth)acrylate, propoxylated glyceryl tri(meth)acrylates, cyclohexyl (meth)acrylate, isobutyl (meth)acrylate, and tertiary-butyl (meth)acrylate.

11. The composition of claim 8, wherein the electron deficient olefin is a 2-cyanoacrylate within structure I: ##STR00041## wherein R.sup.1 is a member selected from the group consisting of C.sub.1-16 alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, aryl, allyl and haloalkyl groups.

12. The composition of claim 8, wherein the electron deficient olefin is a 2-cyanoacrylate selected from the group consisting of methyl cyanoacrylate, ethyl cyanoacrylate, propyl cyanoacrylates, butyl cyanoacrylates, octyl cyanoacrylates, allyl cyanoacrylate, propargyl cyanoacrylate, -methoxyethyl cyanoacrylate and combinations thereof.

13. The composition of claim 8, wherein the electron deficient olefin is a methylidene malonate within structure II: ##STR00042## wherein R.sup.2 and R.sup.3 are each independently selected from alkyl, alkoxyalkyl, cycloalkyl, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, oxirane, episulfide, and oxetane groups.

14. The composition of claim 8, further comprising: (a) a stabilizer package comprising at least one free radical stabilizer and at least one anionic stabilizer; and (b) optionally, one or more additives selected from the group consisting of cure accelerators, thickeners, thixotropes, tougheners, thermal resistance-conferring agents, adhesion promoters and plasticizers.

15. The composition of claim 8, wherein the cure system is present and assists cure by a free radical mechanism, an ionic initiation, or a condensation reaction.

16. The composition of claim 14, wherein the cure system is triggered by exposure to photoirradiation, elevated temperature conditions, moisture, metal, air or anaerobic conditions and combinations thereof.

17. The composition of claim 8, further comprising a compound having a curable functional group selected from (meth)acrylates, acrylonitriles, acrylamides, vinyls, allyls, styrenes, maleimides, itaconimides, and nadimides.

18. The composition of claim 17, wherein the (meth)acrylate compound is selected from 2(2-ethoxyethoxy) ethyl (meth)acrylate, 2-phenoxyethyl (meth)acrylate, 3,3,5 trimethylcyclohexyl (meth)acrylate, alkoxylated lauryl (meth)acrylate, alkoxylated phenol (meth)acrylate, alkoxylated tetrahydrofurfuryl (meth)acrylate, caprolactone (meth)acrylate, cyclic trimethylolpropane formal (meth)acrylate, dicyclopentadienyl (meth)acrylate, diethylene glycol methyl ether (meth)acrylate, ethoxylated hydroxyethyl (meth)acrylates, ethoxylated nonyl phenol (meth)acrylates, isobornyl (meth)acrylate, isodecyl (meth)acrylate, isooctyl (meth)acrylate, lauryl (meth)acrylate, methoxy polyethylene glycol mono(meth)acrylates, octyldecyl (meth)acrylate, propoxylated allyl (meth)acrylates, stearyl (meth)acrylate, tetrahydrofurfuryl (meth)acrylates, tridecyl (meth)acrylate, triethylene glycol ethyl ether (meth)acrylates, 1,12-dodecanediol di(meth)acrylate, 1,3-butylene glycol di(meth)acrylate, 1,4-butanediol di(meth)acrylate, 1,6-hexanediol di(meth)acrylate, alkoxylated aliphatic di(meth)acrylate, alkoxylated cyclohexane dimethanol di(meth)acrylate, alkoxylated hexanediol di(meth)acrylate, alkoxylated neopentyl glycol di(meth)acrylate, cyclohexane dimethanol di(meth)acrylate, diethylene glycol di(meth)acrylate, dipropylene glycol di(meth)acrylate, ethoxylated bisphenol a di(meth)acrylates, ethylene glycol di(meth)acrylate, neopentyl glycol di(meth)acrylate, polyethylene glycol di(meth)acrylates, polypropylene glycol di(meth)acrylates, tetraethylene glycol di(meth)acrylate, tricyclodecane dimethanol di(meth)acrylate, triethylene glycol di(meth)acrylate, tripropylene glycol di(meth)acrylate, di-trimethylolpropane tetra(meth)acrylate, dipentaerythritol penta(meth)acrylate, ethoxylated pentaerythritol tetra(meth)acrylates, pentaerythritol tetra(meth)acrylate, ethoxylated trimethylolpropane tri(meth)acrylates, pentaerythritol tri(meth)acrylate, propoxylated glyceryl tri(meth)acrylates, cyclohexyl (meth)acrylate, isobutyl (meth)acrylate, and tertiary-butyl (meth)acrylate.

Description

DETAILED DESCRIPTION OF THE INVENTION

(1) As noted above, the present provides broadly in one aspect a curable composition comprising:

(2) (a) at least one electron deficient olefin; and

(3) (b) at least one compound having at least one electron deficient olefin functional group and at least one functional group selected from (i) (meth)acrylic esters, (ii) acrylonitriles, (iii) acrylamides, (iv) styryl functional groups, or (v) electron deficient olefin functional groups.

(4) In addition, as component (c) a cure system may optionally be included.

(5) Also, as optional component (d) at least one compound other than component (b) having at least one functional group selected from (i) (meth)acrylic esters, (ii) acrylonitriles, (iii) acrylamides, or (iv) styryl functional groups, and combinations thereof may be included.

(6) The electron deficient olefin of (a) may be selected from 2-cyanoacrylates, methylidene malonates, cyanopentadienoates and combinations thereof. Of course, multifunctional versions of these electron deficient olefins where the functionality may be the same or different are also embraced by the term electron deficient olefin.

(7) The 2-cyanoacrylate may be within structure I:

(8) ##STR00002##
where R.sup.1 is selected from C.sub.1-16 alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, aryl, allyl and haloalkyl groups. For instance, the 2-cyanoacrylate may be selected from methyl cyanoacrylate, ethyl cyanoacrylate, propyl cyanoacrylates, butyl cyanoacrylates, octyl cyanoacrylates, allyl cyanoacrylate, propargyl cyanoacrylate, -methoxyethyl cyanoacrylate and combinations thereof.

(9) The methylidene malonate may be within structure II:

(10) ##STR00003##
where R.sup.2 and R.sup.3 are each independently selected from alkyl, alkoxyalkyl, cycloalkyl, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, oxirane, thiirane, oxetane, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, aryl, allyl and haloalkyl groups. For instance, C.sub.1-16 alkyl or C.sub.2-16 dialkyl (such as dimethyl or diethyl) methylidene malonates, C.sub.2-16 alkyl or C.sub.4-16 dialkenyl (such as diallyl) methylidene malonates, or alkyl alkenyl (such as methylallyl methylenemalonate described in U.S. Pat. Nos. 4,056,543 4,160,864) or methylidene malonic diesters described in U.S. Pat. No. 5,142,098 and De Keyser et al., J. Org. Chem., 53, 4859 (1988).

(11) The cyanopentadienoates may be within structure

(12) ##STR00004##
where R is alkyl, alkenyl, or alkoxy.

(13) For instance, when R is ethyl, allyl, methoxyethyl, or ethoxyethyl, 2-cyano-2,4-pentadienoates are presented, such as are described in U.S. Pat. No. 6,291,544.

(14) The compounds of (a) should be present in the curable composition in an amount of between 5 and 95% by weight of the composition.

(15) The compounds of (b) having at least one electron deficient olefin functional group and at least one functional group selected from (i) (meth)acrylic esters, (ii) acrylonitriles, (iii) acrylamides, (iv) styryl functional groups, or (v) electron deficient olefin functional groups, are embraced by structure III

(16) ##STR00005##
where X is (i) an electron withdrawing group, or

(17) (ii) Y;

(18) Y is

(19) ##STR00006##

(20) where D is selected from H, alkyl and aryl, Z, attached via the Q substituted carbon, is either (a)

(21) ##STR00007## where Q is i. an electron withdrawing group or ii. a first reactive functionality, (b)

(22) ##STR00008## where Q is an electron withdrawing group, a C.sub.1-4 alkyl group, a phenyl or substituted phenyl group, or (c) a second reactive functionality,

(23) g is 1-12; and

(24) n is 0 or 1.

(25) Where X in the compound of structure III is an electron withdrawing group, X may be selected from CN, CO.sub.2R, CO.sub.2H, COCl, COR, COPO(OR).sub.2, COPOR.sub.2, SO.sub.2R, SO.sub.3R and NO.sub.2, where R is C.sub.1-4. X may also be Y, as noted above.

(26) Y in the compound of structure III is

(27) ##STR00009##
where D is selected from H, alkyl or aryl, Z attached to a Q substituted carbon is

(28) ##STR00010##
or Z is

(29) ##STR00011##
where Q is

(30) (a) an electron withdrawing group selected from CN, CO.sub.2R, CO.sub.2H, COCl, COR, COPO(OR).sub.2, COPOR.sub.2, SO.sub.2R, SO.sub.3R or NO.sub.2, where R is C.sub.1-4,

(31) (b) a first reactive functionality selected from amides or thioamides, or

(32) (c) a C.sub.1-4 alkyl group, or a phenyl or substituted phenyl group, and

(33) g is 1.

(34) Y may also be

(35) ##STR00012##
where D is selected from H, alkyl or aryl, Z is a second reactive functionality selected from acrylonitrile, (meth)acrylates, acrylamindes, styrenes, maleimides, itaconimides, or nadimides, and g is 1.

(36) The free radically curable functional group on the compound embraced by structure III is selected from (meth)acrylates, acrylonitriles, acrylamides, styrenes, maleimides, itaconimides, or nadimides.

(37) The ionically curable functional group on the compound embraced by structure III is selected from cyanoacrylates, methylidene malonates or cyanopentadienoates.

(38) Structure III of component (b) also embraces more specifically structure IV

(39) ##STR00013##
where X is an electron withdrawing group or E,

(40) E is as shown,

(41) ##STR00014##
is a reactive functionality, D is selected from H, alkyl or aryl, n is 0 or 1, g is 1, and A, B, 1, 2, 3, 4, 5, and 6 are each references to bond designations.

(42) Structure III of compound (b) may also embrace more specifically structure V

(43) ##STR00015##
where X is an electron withdrawing group or F, D is selected from H, alkyl or aryl, Z is a reactive functionality (such as a second reactive functionality selected from acrylonitrile, (meth)acrylates, acrylamindes, styrenes, maleimides, itaconimides, or nadimides),

(44) ##STR00016##
where Q is (a) an electron withdrawing group selected from CN, CO.sub.2R, CO.sub.2H, COCl, COR, COPO(OR).sub.2, COPOR.sub.2, SO.sub.2R, SO.sub.3R or NO.sub.2, where R is C.sub.1-4,

(45) (b) a first reactive functionality selected from amides or thioamides, or

(46) (c) a C.sub.1-4 alkyl group, or a phenyl or substituted phenyl group,

(47) n is 0 or 1 and g is 1.

(48) Representative examples of compound (b) include cyanoacryloyloxy-alphamethylethacrylate, cyanoacryloyloxy-methylalphamethylacrylonitrile, and cyanoacryloyloxy-ethylmethacrylate.

(49) Examples of compounds of (b) may be selected from the specific compounds listed below

(50) ##STR00017##
where Rc is H or CH.sub.3 and Rd is H, p-MeO or p-CH.sub.3

(51) ##STR00018##
where in the last two compounds n is 2, 3 or 4 and Q is H or CH.sub.3, desirably n is 2 and Q is CH.sub.3.

(52) Examples of such multifunctional electron deficient olefins include bis-cyanoacrylates, bis-methylidene malonates, and bis-cyanopentadienoates.

(53) Bis-cyanoacrylates are embraced by structure IA

(54) ##STR00019##
where R in structure IA is selected from (CH.sub.2).sub.n, with n being 2, 3, 4, 5, 6, 8, 9, 10, or 12, such as a linear or branched chain alkylene like CH(CH.sub.3)CH.sub.2CH.sub.2, CH.sub.2C(CH.sub.3).sub.2CH.sub.2 or CH(CH.sub.3)CH.sub.2CH.sub.2CH(CH.sub.3), or alkylene substituted by halogen like fluorine such as CH.sub.2(CF.sub.2).sub.2CH.sub.2 or interrupted by a heteroatom like oxygen or silyloxy such as (CH.sub.2).sub.4O(CH.sub.2).sub.4 or CH.sub.2Si (CH.sub.3).sub.2OSi (CH.sub.3).sub.2CH.sub.2, respectively; alkenyl such as CH.sub.2CHCHCH.sub.2 or alkynyl such as

(55) ##STR00020##
or arylene like phenylene such as

(56) ##STR00021##
or

(57) ##STR00022##
respectively.

(58) Of course, multifunctional versions of the compounds of (b) where the functionality may be the same or different are also embraced. Examples of such multifunctional versions include multi (meth)acrylates, like di(meth)acrylates and tri(meth)acrylates, and divinyl benzene.

(59) The compounds of (b) should be present in the curable composition in an amount of between 0.5 and 50% by weight.

(60) The cure system of (c) assists cure by a free radical mechanism, an ionic initiation, or a condensation reaction.

(61) The cure system when assisting cure by way of a free radical mechanism may be selected from thermal initiators, photoinitiators, metal catalysts, exposure to air or by removal of air. Here, the free radical cure system should be present in an amount of about 1-3% by weight. The cure system may also involve the substrate itself to which compositions according to the invention are applied.

(62) The cure system when assisting cure by way of an ionic initiation may be selected from onium salts for example, such as substituted or unsubstituted diphenyl iodonium or triphenyl sulfonium salts bearing non nucleophilic anions such as AsF.sub.6, SbF.sub.6, PF.sub.6, BF.sub.4 and others well known to those skilled in the art of cationic polymerisation. Metal salts may also be used here with similar non-nucleophilic counterions. Here, the ionic initiated cure system should be present in an amount of about 1-3% by weight.

(63) The cure system when assisting cure by way of a condensation reaction involve monomers reactive towards moisture such as those bearing alkoxy silane or isocyanate functions and may further comprise cure catalysts, such as tin or zinc octanoates or laurylates. Here, the condensation cure system should be present in an amount of 0.1-10% by weight with respect to the monomers and 1-3% by weight with respect to any catalysts used.

(64) The curable composition so defined may also include (d) at least one compound other than compounds of (b) having at least one curable functional group other than an electron deficient olefin. This curable functional group may be free radically curable, ionically curable or condensation curable.

(65) Where the curable functional group on the compound of (d) is a free radically curable functional group examples include (meth)acrylates, acrylonitriles, acrylamides, vinyls, allyls, styrenes, maleimides, itaconimides, and nadimides. Examples of (meth)acrylates for instance include 2(2-ethoxyethoxy) ethyl (meth)acrylate, 2-phenoxyethyl (meth)acrylate, 3,3,5 trimethylcyclohexyl (meth)acrylate, alkoxylated lauryl (meth)acrylate, alkoxylated phenol (meth)acrylate, alkoxylated tetrahydrofurfuryl (meth)acrylate, caprolactone (meth)acrylate, cyclic trimethylolpropane formal (meth)acrylate, dicyclopentadienyl (meth)acrylate, diethylene glycol methyl ether (meth)acrylate, ethoxylated hydroxyethyl (meth)acrylates, ethoxylated nonyl phenol (meth)acrylates, isobornyl (meth)acrylate, isodecyl (meth)acrylate, isooctyl (meth)acrylate, lauryl (meth)acrylate, methoxy polyethylene glycol mono(meth) acrylates, octyldecyl (meth)acrylate, propoxylated allyl (meth)acrylates, stearyl (meth)acrylate, tetrahydrofurfuryl (meth)acrylates, tridecyl (meth)acrylate, triethylene glycol ethyl ether (meth)acrylates, 1,12-dodecanediol di(meth)acrylate, 1,3-butylene glycol di(meth)acrylate, 1,4-butanediol di(meth)acrylate, 1,6-hexanediol di(meth)acrylate, alkoxylated aliphatic di(meth)acrylate, alkoxylated cyclohexane dimethanol di(meth)acrylate, alkoxylated hexanediol di(meth)acrylate, alkoxylated neopentyl glycol di (meth)acrylate, cyclohexane dimethanol di(meth)acrylate, diethylene glycol di(meth)acrylate, dipropylene glycol di(meth)acrylate, ethoxylated bisphenol a di(meth)acrylates, ethylene glycol di(meth)acrylate, neopentyl glycol di(meth)acrylate, polyethylene glycol di(meth)acrylates, polypropylene glycol di(meth)acrylates, tetraethylene glycol di(meth)acrylate, tricyclodecane dimethanol di(meth)acrylate, triethylene glycol di(meth)acrylate, tripropylene glycol di(meth)acrylate, di-trimethylolpropane tetra(meth)acrylate, dipentaerythritol penta(meth)acrylate, ethoxylated pentaerythritol tetra(meth)acrylates, pentaerythritol tetra(meth)acrylate, ethoxylated trimethylolpropane tri(meth)acrylates, pentaerythritol tri(meth)acrylate, propoxylated glyceryl tri(meth)acrylates, cyclohexyl (meth)acrylate, isobutyl (meth)acrylate, and tertiarybutyl (meth)acrylate.

(66) Where the curable functional group on the compound of (d) is an ionically curable functional group examples include oxirane, thiirane, oxetane, vinyl ether, or N-vinyl carbazole.

(67) Where the curable functional group on the compound of (d) is condensation curable examples include alkoxy silane and isocyanates, examples of which are given below.

(68) Compounds of (d) may also possess two or more different reactive functionalities. For instance, compounds of (d) may be selected from

(69) ##STR00023##
where Rb is H or alkyl, R.sub.4 is alkyl, such as methyl or ethyl, and v is 2-4.

(70) Compounds of (d) may also be selected from

(71) ##STR00024##
where R.sub.1, R.sub.2, and R.sub.3 are the same or different and are selected from C.sub.1-4 alkyl or alkoxy, Rb is H or alkyl, and v is 1-3.

(72) The inventive composition may also include:

(73) (a) a stabilizer package comprising at least one free radical stabilizer and at least one anionic stabilizer; and

(74) (b) optionally, one or more additives selected from cure accelerators, thickeners, thixotropes, tougheners, thermal resistance-conferring agents, adhesion promoters or plasticizers.

(75) In another aspect the invention provides a method of preparing the so described compositions. For instance, the method includes providing in any order (a) at least one electron deficient olefin; (b) at least one compound having at least one electron deficient olefin functional group and at least one functional group selected from (i) (meth)acrylic esters, (ii) acrylonitriles, (iii) styryl functional groups, or (iv) electron deficient olefin functional groups; and (c) optionally, a cure system. The method may also include providing optional component (d) (at least one compound other than component (b) having at least one functional group selected from (i) (meth)acrylic esters, (ii) acrylonitriles, (iii) acrylamides, or (iv) styryl functional groups, and combinations thereof) and/or the stabilizer package and additives noted above.

(76) In still another aspect the invention provides a method of using the so described compositions to bond together two or more substrates. The substrates may be constructed from a variety of materials, such as metals, ceramics, glasses, plastics, composites, woods, natural and synthetic rubbers, stone, textiles and fibers including carbon and inorganic fibers, non-woven fabrics leathers, living tissue including hair, skin and other organs and plant tissue.

(77) In yet another aspect the invention provides reaction products of the so described compositions.

EXAMPLES

Example 1

(78) ##STR00025##

(79) 2-Phenylallyl bromide is prepared according to the method of Pines, Alul and Kolobieski, J. Org. Chem., 22, 1113 (1957) via bromination of alpha-methylstyrene with N-bromosuccinimide.

(80) An equimolar quantity of 2-phenylallyl bromide and the potassium salt of cyanoacetic acid are reacted in refluxing toluene stabilised by 3% hydroquinone. The reaction is monitored by GC and stopped when the consumption of the bromide is complete. The reaction mixture is cooled, filtered and concentrated in vacuo to yield an alpha-methylstyrene substituted cyanoacetate, shown in the reaction sequence above.

(81) In a separate step, PRIMENE 81-R imine was prepared by reaction of PRIMENE 81-R amine with a stoichiometric equivalent of paraformaldehyde and removal of water of condensation. 1H NMR 60 MHz (CDCl.sub.3) 2H s (br) 7.45 ppm and FTIR (1650 cm.sup.1).

(82) Subsequently PRIMENE 81-R iminium-MSA was prepared from PRIMENE 81-R imine by adding dropwise with stirring methane sulfonic acid at ice water bath temperature, yielding a pale yellow iminium salt.

(83) To a stirring mixture of PRIMENE 81-R iminium-MSA (5.86 g, 20 mmol) and an equimolar equivalent of the alpha-methylstyrene substituted cyanoacetate shown above, is added 1% of hydroquinone and the mixture is degassed for a period of time of 5 minutes at room temperature. Immediately thereafter, the degassed stirring mixture is vacuum distilled (0.2 mbar) at a temperature of 200 C. The styryl-substituted cyanoacrylate ester is collected as a distillate.

(84) In Examples 2-5 below, the title compound sought is shown as a preface to the synthesis in each example to obtain the compound.

Example 2

(85) ##STR00026##

(86) To a stirring mixture of PRIMENE 81-R iminium-MSA (5.86 g, 20 mmol) and

(87) ##STR00027##
(g, 20 mmol), was added 10 mg of hydroquinone and degassed for a period of time of 5 minutes at room temperature. Immediately thereafter, the degassed stirring mixture was vacuum distilled (0.2 mbar) at a temperature of 200 C. The product shown above was collected as a colourless oil (60% purity by GC, 36% yield). .sup.1H NMR (60 MHz, CDCl.sub.3): 7.01 (s, 1H), 6.58 (s, 1H), 6.36 (s, 1H), 5.88 (s, 1H), 4.95 (s, 1H), 4.27 (q, J=6.6 Hz, 2H), 1.30 (t, J=6.6 Hz, 3H); FT-IR (film): 3125.4 (CC), 2937.7, 2875.0, 2238.3 (CN), 1723.8 (b, s, CO), 1641.6 (CC), 1389.2, 1310.6, 1155.5, 1026.7, 803.6 cm.sup.1.

Example 3

(88) ##STR00028##

(89) To a stirring mixture of PRIMENE 81-R iminium-MSA (2.93 g, 10 mmol) and

(90) ##STR00029##
(2.44 g, 10 mmol), was added 10 mg of hydroquinone and degassed for a period of time of 5 minutes at room temperature. Immediately thereafter, the degassed stirring mixture was vacuum distilled (0.1 mbar) at a temperature of 200 C. The triester shown above was collected as a colourless oil (1.7 g, 110-120 C./0.1 mbar, 43% purity by GC, 28% yield). GC/MS shows the sample is a mixture of monomer and acetate (1:1.3); 1H NMR (60 MHz, CDCl.sub.3): 6.51 (s, 1H), 6.34 (s, 2H), 5.86 (s, 1H), 4.94 (s, 1H), 4.39-4.04 (m, 4H), 1.42-1.18 (m, 6H); FT-IR (film): 2984.0, 2908.7, 1731.5, 1640.6, 1400.5, 1330.5, 1272.1, 1191.5, 1144.1, 1029.3, 813.1 cm.sup.1.

Example 4

(91) ##STR00030##

(92) To a stirring mixture of PRIMENE 81-R iminium-MSA (2.93 g, 10 mmol) and

(93) ##STR00031##
(1.97 g, 10 mmol), was added 10 mg of hydroquinone and degassed for a period of time of 5 minutes at room temperature. Immediately thereafter, the degassed stirring mixture was vacuum distilled (0.1 mbar) at a temperature of 200 C. The product shown above was collected as a colourless oil (1.7 g, 94-104 C./0.25-0.35 mbar, 80% purity by GC, 65% yield). .sup.1H NMR (60 MHz, CDCl.sub.3): 6.62 (s, 2H), 6.12 (s, 2H), 4.81 (s, 2H), 4.26 (q, J=6.0 Hz, 2H), 1.33 (t, J=6.0 Hz, 3H); FT-IR (film): 3118.4, 2985.8, 2229.9, 1736.1, 1628.7, 1407.3, 1371.9, 1331.0, 1191.8, 1030.2, 805.9 cm.sup.1.

Example 5

(94) ##STR00032##

(95) To a stirring mixture of PRIMENE 81-R iminium-MSA (2.93 g, 10 mmol) and

(96) ##STR00033##
(1.50 g, 10 mmol), was added 10 mg of hydroquinone and degassed for a period of time of 5 minutes at room temperature. Immediately thereafter, the degassed stirring mixture was vacuum distilled (0.2 mbar) at a temperature of 200 C. The dinitrile ester shown above was collected as a colourless oil (0.96 g, 140-160 C./0.2-0.3 mbar, 43% purity by NMR, 25% yield). .sup.1H NMR (60 MHz, CDCl.sub.3): 7.04 (s, 1H), 6.64 (s, 1H), 6.12 (s, 2H), 4.82 (s, 2H); FT-IR (film): 3124.9, 2960.9, 2874.6, 2229.5, 1745.0, 1678.1, 1528.9, 1284.3, 1177.4, 955.0, 802.5 cm.sup.1.

Example A

(97) An adhesive formulation composition is made on a by weight basis from 85% ethylcyanoacrylate, 5% of the hybrid cyanoacryloyloxy-alphamethylethacrylate, 9% triethyleneglycol dimethacrylate, 1% hydroquinone and 50 ppm of methane sulfonic acid with stirring at room temperature.

Example B

(98) An adhesive formulation composition is made on a by weight basis from 80% ethylcyanoacrylate, 10% of the hybrid cyanoacryloyloxy-alphamethylethacrylate, 9% triethyleneglycol dimethacrylate, 1% hydroquinone and 50 ppm of methane sulfonic acid with stirring at room temperature.

Example C

(99) An adhesive formulation composition is made on a by weight basis from 50% ethylcyanoacrylate, 25% of the hybrid cyanoacryloyloxy-alphamethylethacrylate, 24% triethyleneglycol dimethacrylate, 1% hydroquinone and 50 ppm of methane sulfonic acid with stirring at room temperature.

Example D

(100) An adhesive formulation composition is made on a by weight basis from 85% ethylcyanoacrylate, 5% of the hybrid cyanoacryloyloxy-methyl alphamethylacrylonitrile, 9% triethyleneglycol dimethacrylate, 1% hydroquinone and 50 ppm of methane sulfonic acid with stirring at room temperature.

Example E

(101) An adhesive formulation composition is made on a by weight basis from 80% ethylcyanoacrylate, 10% of the hybrid cyanoacryloyloxy-methyl alphamethylacrylonitrile, 9% triethyleneglycol dimethacrylate, 1% hydroquinone and 50 ppm of methane sulfonic acid with stirring at room temperature.

Example F

(102) An adhesive formulation composition is made on a by weight basis from 50% ethylcyanoacrylate, 25% of the hybrid cyanoacryloyloxy-methyl alphamethylacrylonitrile, 24% triethyleneglycol dimethacrylate, 1% hydroquinone and 50 ppm of methane sulfonic acid with stirring at room temperature.

Example G

(103) An adhesive formulation composition is made on a by weight basis from 85% ethylcyanoacrylate, 5% of the hybrid cyanoacryloyloxyethylmethacrylate, 9% triethyleneglycol dimethacrylate, 1% hydroquinone and 50 ppm of methane sulfonic acid with stirring at room temperature.

Example H

(104) An adhesive formulation composition is made on a by weight basis from 80% ethylcyanoacrylate, 10% of the hybrid cyanoacryloyloxyethylmethacrylate, 9% triethyleneglycol dimethacrylate, 1% hydroquinone and 50 ppm of methane sulfonic acid with stirring at room temperature.

Example I

(105) An adhesive formulation composition is made on a by weight basis from 50% ethylcyanoacrylate, 25% of the hybrid cyanoacryloyloxyethylmethacrylate, 24% triethyleneglycol dimethacrylate, 1% hydroquinone and 50 ppm of methane sulfonic acid with stirring at room temperature.

Example J

(106) An adhesive formulation composition is made on a by weight basis from 85% ethylcyanoacrylate, 2.5% of the hybrid cyanoacryloyloxy-alphamethylethacrylate, 2.5% 3-methacryloylpropyltrimethoxysilane, 9% triethyleneglycol dimethacrylate, 1% hydroquinone and 50 ppm of methane sulfonic acid with stirring at room temperature.

Example K

(107) An adhesive formulation composition is made on a by weight basis from 85% ethylcyanoacrylate, 2.5% of the hybrid cyanoacryloyloxy-alphamethylethacrylate, 2.5% 3-methacryloylpropyltrimethoxysilane, 9% triethoxysilane terminated polysiloxane, 1% hydroquinone and 50 ppm of methane sulfonic acid with stirring at room temperature.

Example L

(108) An adhesive formulation composition is made on a by weight basis from 85% ethylcyanoacrylate, 2.5% of the hybrid cyanoacryloyloxy-alphamethylethacrylate, 2.4% methylglycidyl methacrylate, 9% bisphenol-A-diglycidyl ether, and 1% hydroquinone with stirring at room temperature. Sulfur dioxide is used as stabiliser.

Example M

(109) An adhesive formulation composition is made on a by weight basis from 85% ethylcyanoacrylate, 2.5% of the hybrid cyanoacryloyloxyethylmethacrylate, 2.4% methylglycidyl methacrylate, 9% bisphenol-A-diglycidyl ether, and 1% hydroquinone with stirring at room temperature. Sulfur dioxide is used as stabiliser.

Example N

(110) A formulation containing 24% cyanoacryloyloxy-alphamethylethacrylate, 74% isobornylacrylate and 2% of Irgacure 184 was polymerised by exposure to radiation in the electromagnetic spectrum generated by UVALOC UV lamp operating primarily at 366 nm, for a period of time of 20 seconds. A polymer resulted that was insoluble in CDCl.sub.3.

(111) In a comparison under the same conditions, a formulation containing 24% of n-butyl cyanoacrylate, 74% isobornylacrylate and 2% of Irgacure 184 yielded a polymer after exposure to the same conditions. This polymer however was soluble in CDCl.sub.3. 1H NMR analysis of the polymer made with n-butyl cyanoacrylate showed the cyanoacrylate vinyl protons to have disappeared with minor residual vinyl signals from the distinct isobornylacrylate.

Example O

(112) Cyanoacryloyloxy-alphamethylethacrylate was polymerised with the radical initiator, AIBN. In solution, 0.7 mg of AIBN was used with 0.16 g of cyanoacryloyloxy-alphamethylethacrylate in 0.72 ml of THF. Anionic polymerisation was inhibited by washing the glassware with HCl, prior to use. Sealed tubes containing the three components were exposed to a temperature of 60 C. to thermally polymerise the composition.

(113) .sup.1H NMR analysis revealed polymer structures shown below were observed. The relative concentration of the cyclic lactone structures could be varied with conditions of polymerisation. Thus, in two solution polymerisation experiments, the second taking twice as long as the first at a temperature of 60 C., the following conversion results shown below were obtained. I is a six membered cyclic lactone, II is a five membered cyclic lactone, III is a polymer fragment with pendant acrylate functions, and IV is a polymer fragment with pendant cyanoacrylate functions.

(114) ##STR00034##

(115) TABLE-US-00001 I% II% III% IV% Run 1 41 51 8 Run 2 ~15 82 0

(116) A similar reaction to that described above was performed with allylcyanoacrylate instead of cyanoacryloyloxy-alphamethylethacrylate, with all other components and reaction conditions remaining the same. Allylcyanaoacrylate is structurally related to cyanoacryloyloxy-alphamethylethacrylate. This reaction afforded soluble polymers without the characteristic 70 ppm OCH.sub.2 signal in .sup.13C NMR attributed to -butyrolactone (I) or -valerolactone (II), that were distinct in the spectra of the soluble samples (low conversion) of the latter monomer.

Example P

(117) Cyanoacryloyloxy-alphamethylethacrylate was radically copolymerised with methyl methacrylate (50:50 mol ratios) using conditions similar to those described above in Example O, Run 1. Here, soluble polymers were obtained but only at a very low conversion. The remaining portion of the reaction mixture was crosslinked. For the soluble portion, the polymer formed had a similar make up to the ratio of the initial feed of the two monomers (42:50) as determined by .sup.1H NMR analysis.

Example Q

(118) Radical photopolymerisation of cyanoacryloyloxy-alphamethylethacrylate using Irgacure 184 was carried out in a differential photocalorimeter (TA Instruments Q100). Polymerisation at a high conversion (>80%) was observed to occur in about 60 seconds.

Example R

(119) An acid containing sample of cyanoacryloyloxy-alphamethylethacrylate was polymerised anionically by the addition of <0.5% of NaOH in dilute THF solution. The homopolymers formed were soluble.

(120) Copolymerisation of cyanoacryloyloxy-alphamethylethacrylate with ethylcyanoacrylate was also initiated by NaOH in dilute THF solution.

Example S

(121) N-Butyl cyanoacrylate and ethylcyanoacrylate were formulated with 2% by weight of Irgacure 184 and used as controls. These controls were exposed to radiation in the electromagnetic spectrum generated from a UVALOC 1000 lamp. In the n-butyl cyanoacrylate sample no sign of cure was observed to occur even after 60 seconds of exposure to the radiation generated from the UVALOC 1000 lamp or when the sample was first heated to a temperature of 80 C. and then exposed for 60 seconds to the radiation generated from the UVALOC 1000 lamp. In the ethylcyanoacrylate sample, some stringing was observed after 20 seconds of exposure and after 60 seconds of exposure only a weak gel was observed.

(122) Cyanoacryloyloxyethylmethacrylate was used as the basis for five samples formulated as described below.

(123) S1: with 2% Irgacure 184

(124) S2: with 50% n-butylcyanoacrylate and 2% Irgacure 184

(125) S3: with 75% n-Butylcyanoacrylate and 2% Irgacure 184

(126) S4: with 50% ethylcyanoacrylate and 2% Irgacure 184

(127) S5: with 25% ethylcyanoacrylate and 2% Irgacure 184

(128) Each of the five samples was exposed to radiation in the electromagnetic spectrum generated from a UVALOC 1000 lamp as follows, and the results obtained are detailed below:

(129) S1: 20 seconds; cured, dry to touch and completely insoluble in THF at room temperature even for protracted periods of time (>24 hours) or at elevated temperature.

(130) S2: 20 seconds; gel. 40 seconds; insoluble polymer (THF).

(131) S3: 20 seconds; still liquid. 40 seconds; partial cure. 60 seconds; cured (film insoluble in THF). 80 seconds; hard cured polymer insoluble in THF.

(132) S4: 20 seconds; strong gel. 40 seconds; completely cured and insoluble in THF.

(133) S5: 20 seconds; well cured and insoluble polymer.

Example T

(134) An adhesive joint was made from sample S4 of Example S by applying a few drops of the sample to a glass substrate and mating it with another glass substrate to form an assembly with the substrates arranged in off setting manner and confining the sample. The assembly was exposed for 20 seconds to radiation in the electromagnetic spectrum generated from a UVALOC 1000 lamp. A strong bond was observed to form, with substrate failure outside the bonded area noted after stressing the assembly in tensile shear mode.